{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:47:17Z","timestamp":1789505237453,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T00:00:00Z","timestamp":1328659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s11940-012-0165-x","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T04:50:40Z","timestamp":1328590240000},"page":"137-149","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutics in Huntington\u2019s Disease"],"prefix":"10.1007","volume":"14","author":[{"given":"Annie","family":"Killoran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Biglan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,8]]},"reference":[{"key":"165_CR1","first-page":"317","volume":"26","author":"G Huntington","year":"1872","unstructured":"Huntington G. On chorea. Med Surg Rep. 1872;26:317\u201321.","journal-title":"Med Surg Rep"},{"key":"165_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"165_CR3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","volume":"23","author":"JG Hodgson","year":"1999","unstructured":"Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington\u2019s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23:181\u201392.","journal-title":"Neuron"},{"key":"165_CR4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO. Huntington\u2019s disease. Lancet. 2007;369:218\u201328.","journal-title":"Lancet"},{"key":"165_CR5","doi-asserted-by":"crossref","unstructured":"Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington\u2019s disease. Mov Disord. 2011 Oct 13 (Epub ahead of print). This is a recent detailed review of the pharmacological aspects of the medications currently used in HD and of those being evaluated for future use.","DOI":"10.1002\/mds.23953"},{"key":"165_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","volume":"5","author":"OR Adam","year":"2008","unstructured":"Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5:181\u201397.","journal-title":"Neurotherapeutics"},{"key":"165_CR7","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mds.21971","volume":"23","author":"W Phillips","year":"2008","unstructured":"Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington\u2019s disease. Mov Disord. 2008;23:1491\u2013504.","journal-title":"Mov Disord"},{"issue":"1","key":"165_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83\u201398.","journal-title":"Lancet Neurol"},{"key":"165_CR9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366\u201372.","journal-title":"Neurology"},{"key":"165_CR10","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1345\/aph.1M582","volume":"44","author":"LH Poon","year":"2010","unstructured":"Poon LH. Role of tetrabenazine for Huntington\u2019s disease-associated chorea. Ann Pharmacother. 2010;44:1080\u20139.","journal-title":"Ann Pharmacother"},{"key":"165_CR11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","volume":"25","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington\u2019s disease: an open label study. Clin Neuropharmacol. 2002;25:263\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"165_CR12","first-page":"69","volume":"14","author":"F Squitieri","year":"2001","unstructured":"Squitieri F, Cannella M, Piorcellini A, et al. Shortterm effects of olanzapine in Huntington\u2019s disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:69\u201372.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"165_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","volume":"19","author":"C Dallocchio","year":"1999","unstructured":"Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19:101\u20133.","journal-title":"J Clin Psychopharmacol."},{"key":"165_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10401230701844802","volume":"20","author":"K Duff","year":"2008","unstructured":"Duff K, Beglinger LJ, O\u2019Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease. Ann Clin Psychiatry. 2008;20:1\u20133.","journal-title":"Ann Clin Psychiatry"},{"key":"165_CR15","first-page":"282","volume":"4","author":"S Gim\u00e9nez-Rold\u00e1n","year":"1989","unstructured":"Gim\u00e9nez-Rold\u00e1n S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia. 1989;4:282\u20137.","journal-title":"Neurologia"},{"key":"165_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5694\/j.1326-5377.1976.tb140550.x","volume":"1","author":"JB Peiris","year":"1976","unstructured":"Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976;1:225\u20137.","journal-title":"Med J Aust"},{"key":"165_CR17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","volume":"47","author":"M Alpay","year":"2006","unstructured":"Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington\u2019s disease. Psychosomatics. 2006;47:70\u20132.","journal-title":"Psychosomatics"},{"key":"165_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-6-11","volume":"6","author":"C Saft","year":"2006","unstructured":"Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington\u2019s Disease patients: a case series. BMC Neurol. 2006;6:11.","journal-title":"BMC Neurol"},{"key":"165_CR19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","volume":"25","author":"AK Holl","year":"2010","unstructured":"Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington\u2019s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25:46\u201350.","journal-title":"Int Clin Psychopharmacol"},{"key":"165_CR20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","volume":"30","author":"W Duan","year":"2008","unstructured":"Duan W, Peng Q, Masuda N, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington\u2019s disease. Neurobiol Dis. 2008;30:312\u201322.","journal-title":"Neurobiol Dis"},{"key":"165_CR21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.20075","volume":"55","author":"W Duan","year":"2004","unstructured":"Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol. 2004;55:590\u20134.","journal-title":"Ann Neurol"},{"key":"165_CR22","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","volume":"19","author":"M Tommaso de","year":"2004","unstructured":"de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington\u2019s disease. Mov Disord. 2004;19:1516\u20138.","journal-title":"Mov Disord"},{"key":"165_CR23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","volume":"30","author":"M Tommaso de","year":"2007","unstructured":"de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years\u2019 follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30:43\u20136.","journal-title":"Clin Neuropharmacol"},{"key":"165_CR24","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","volume":"67","author":"E Cubo","year":"2006","unstructured":"Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67:1268\u201371.","journal-title":"Neurology"},{"key":"165_CR25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2190\/72U2-FQ94-RVK5-6J5C","volume":"25","author":"GR Brown","year":"1995","unstructured":"Brown GR. The use of methylphenidate for cognitive decline associated with HIV disease. Int J Psychiatry Med. 1995;25:21\u201337.","journal-title":"Int J Psychiatry Med"},{"key":"165_CR26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3810\/pgm.2010.09.2200","volume":"122","author":"TE Brown","year":"2010","unstructured":"Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med. 2010;122:42\u201351.","journal-title":"Postgrad Med."},{"key":"165_CR27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/JCP.0b013e3181b2ac0a","volume":"29","author":"LJ Beglinger","year":"2009","unstructured":"Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29:484\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"165_CR28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1531-8257(200001)15:1<171::AID-MDS1031>3.0.CO;2-Y","volume":"15","author":"E Tan","year":"2000","unstructured":"Tan E, Jankovic J, Ondo W. Bruxism in Huntington\u2019s disease. Mov Disord. 2000;15:171\u20133.","journal-title":"Mov Disord"},{"key":"165_CR29","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s00415-011-5998-9","volume":"258","author":"P Burbaud","year":"2011","unstructured":"Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258:1670\u20135.","journal-title":"J Neurol"},{"key":"165_CR30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.parkreldis.2006.08.005","volume":"13","author":"WG Ondo","year":"2007","unstructured":"Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington\u2019s disease. Parkinsonism Relat Disord. 2007;13:453\u20134.","journal-title":"Parkinsonism Relat Disord"},{"key":"165_CR31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","volume":"57","author":"Huntington Study Group","year":"2001","unstructured":"Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease. Neurology. 2001;57:397\u2013404.","journal-title":"Neurology"},{"key":"165_CR32","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2032dG. Neurology. 2006;66:250\u20132.","journal-title":"Neurology"},{"key":"165_CR33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG Yebenes de","year":"2011","unstructured":"de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. on behalf of the MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease: a phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2011;10:1049\u201357.","journal-title":"Lancet Neurol"},{"key":"165_CR34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/187652970110401007","volume":"4","author":"D Zeef","year":"2011","unstructured":"Zeef D, Schaper F, Vlamings R, et al. Deep brain stimulation in Huntington\u2019s disease: the current status. Open Neurosurg J. 2011;4:7\u201310.","journal-title":"Open Neurosurg J"},{"key":"165_CR35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.58.5.687","volume":"58","author":"RA Hauser","year":"2002","unstructured":"Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington\u2019s disease. Neurology. 2002;58:687\u201395.","journal-title":"Neurology"},{"key":"165_CR36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1073858410386236","volume":"17","author":"AL Southwell","year":"2011","unstructured":"Southwell AL, Patterson PH. Gene therapy in mouse models of Huntington disease. Neuroscientist. 2011;17:153\u201362.","journal-title":"Neuroscientist"},{"key":"165_CR37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0303-8467(80)90017-7","volume":"82","author":"P Jongen","year":"1980","unstructured":"Jongen P, Renier W, Gabreels F. Seven cases of Huntington\u2019s disease in childhood and levodopa induced improvement in the hypokinetic\u2014rigid form. Clin Neurol Neurosurg. 1980;82:251\u201361.","journal-title":"Clin Neurol Neurosurg"},{"key":"165_CR38","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/mds.20530","volume":"20","author":"P Striano","year":"2005","unstructured":"Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord. 2005;20:1610\u20134.","journal-title":"Mov Disord"},{"key":"165_CR39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.wnf.0000186648.93612.a5","volume":"28","author":"M Tommaso de","year":"2005","unstructured":"de Tommaso M, Di Fruscolo O, Sciruicchio V, et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol. 2005;28:280\u20134.","journal-title":"Clin Neuropharmacol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0165-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-012-0165-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0165-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T01:05:57Z","timestamp":1640653557000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-012-0165-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["165"],"URL":"https:\/\/doi.org\/10.1007\/s11940-012-0165-x","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,8]]}}}